Expert Outlook: Viridian Therapeutics Through The Eyes Of 10 Analysts
Expert Outlook: Viridian Therapeutics Through The Eyes Of 10 Analysts
专家展望：通过10位分析师的视角看Viridian Therapeutics
An in...Across the recent three months, 10 analysts have shared their insights on Viridian Therapeutics (NASDAQ:VRDN), expressing a variety of opinions spanning from bullish to bearish.
在最近的三个月里，10位分析师分享了他们对维里迪安治疗公司（纳斯达克:VRDN）的见解，表达了从看好到看淡的各种意见。
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
在下面的表格中，您将找到他们最近评级的摘要，揭示了过去30天情绪的变化，并与前几个月进行了比较。
Analysts have set 12-month price targets for Viridian Therapeutics, revealing an average target of $37.2, a high estimate of $47.00, and a low estimate of $27.00. Observing a downward trend, the current average is 0.05% lower than the prior average price target of $37.22.
分析师为Viridian Therapeutics设定了12个月的价格目标，平均目标为37.2美元，最高估计为47.00美元，最低估计为27.00美元。观察到下行趋势，当前平均值比之前的平均价格目标37.22美元低0.05%。
Understanding Analyst Ratings: A Comprehensive Breakdown
分析师评级：全面解析
An in...
对近...
登录免费看全文
登录/注册
热门讨论
中美谈话新契机，通胀不再？
🎙️讨论： 1. 你认为特朗普上台后，对华政策将如何影响中国资产？ 2. 美股市场通胀风险下降，有哪些利好板块？
Moomoo News Global
2024/12/09 20:23
中国将在未来一年采取"适度宽松"的货币政策，这是自2011年以来的首次转向宽松。